
    
      The investigators are undertaking a single-center, single-arm study of 50 lower risk
      myelodysplastic syndrome patients with transfusion dependent from Shandong University Qilu
      Hospital . All the participants are selected to receive ultra small dose decitabine treatment
      (given intravenously at a dose of 3.5mg/m2, qd x 5d, every four weeks for one cycle). A
      routine blood examination is performed twice every week. Bone marrow (BM) is examined with
      routine aspirate smear and G-banding analysis every 1-2 treatment courses to evaluate
      responses.Adverse events are also recorded throughout the study.
    
  